```
L1             1 S US 20070123518/PN

     FILE 'REGISTRY' ENTERED AT 08:56:51 ON 14 DEC 2009
L2             1 S 50-18-0/RN
                 SET NOTICE 1 DISPLAY
                 SET NOTICE LOGIN DISPLAY

     FILE 'REGISTRY' ENTERED AT 08:57:06 ON 14 DEC 2009
L3             1 S 50-23-7/RN
                 SET NOTICE 1 DISPLAY
                 SET NOTICE LOGIN DISPLAY

     FILE 'REGISTRY' ENTERED AT 08:57:22 ON 14 DEC 2009
L4             1 S 57-27-2/RN
                 SET NOTICE 1 DISPLAY
                 SET NOTICE LOGIN DISPLAY

     FILE 'REGISTRY' ENTERED AT 08:57:37 ON 14 DEC 2009
L5             1 S 439-14-5/RN
                 SET NOTICE 1 DISPLAY
                 SET NOTICE LOGIN DISPLAY

     FILE 'REGISTRY' ENTERED AT 08:57:58 ON 14 DEC 2009
L6             1 S 12794-10-4/RN
                 SET NOTICE 1 DISPLAY
                 SET NOTICE LOGIN DISPLAY

     FILE 'REGISTRY' ENTERED AT 08:58:15 ON 14 DEC 2009
L7             1 S 51753-57-2/RN

L7   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2009 ACS on STN
RN   51753-57-2  REGISTRY
CN   2H-1,4-Benzodiazepin-2-one, 7-bromo-5-(2-chlorophenyl)-1,3-
dihydro-  (CA
     INDEX NAME)
OTHER NAMES:
CN   7-Bromo-5-(2-chlorophenyl)-1,3-dihydrobenzo[e]-1,4-diazepin-2-one
CN   BD 98
CN   Fenazepam
CN   Phenazepam
DR   66173-95-3
MF   C15 H10 Br Cl N2 O
CI   COM
LC   STN Files:   ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS,
BIOTECHNO,
       CA, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CSCHEM, DDFU,
DRUGU,
       EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, RTECS*, SPECINFO,
       TOXCENTER, USPAT2, USPATFULL
         (*File contains numerically searchable property data)
DT.CA  CAplus document type:  Book; Conference; Journal; Patent; Report
RL.P   Roles from patents:  ANST (Analytical study); BIOL (Biological
study);
       PREP (Preparation); PROC (Process); RACT (Reactant or reagent);
USES
       (Uses)
RLD.P  Roles for non-specific derivatives from patents:  BIOL
```

(Biological
study); USES (Uses)
RL.NP Roles from non-patents: ANST (Analytical study); BIOL
(Biological
study); FORM (Formation, nonpreparative); MSC (Miscellaneous);
NANO
(Nanomaterial); PREP (Preparation); PROC (Process); PRP
(Properties);
RACT (Reactant or reagent); USES (Uses)
RLD.NP Roles for non-specific derivatives from non-patents: BIOL
(Biological
study); FORM (Formation, nonpreparative); PREP (Preparation);
PROC
(Process); PRP (Properties); USES (Uses)



SET NOTICE 1 DISPLAY
SET NOTICE LOGIN DISPLAY

FILE 'HCAPLUS' ENTERED AT 09:00:16 ON 14 DEC 2009
L8 110361 S (L2 OR L3 OR L4 OR L5 OR L6 OR L7)
L9 19 S L8 AND HOMEOPATHIC
L10 15 S L9 AND (PY<2004 OR AY<2004 OR PRY<2004)
L11 12 S L9 AND (PY<2003 OR AY<2003 OR PRY<2003)

L11 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Method for the treatment of chronic relapsing lip fissures and
combinations of chronic relapsing lip fissures with exfoliative or
atopic
chelitis
AB Method is disclosed for the treatment of chronic relapsing lip
fissures and combinations of chronic relapsing lip fissures with
exfoliative or atopic chelitis. Method involves administration of
proteolytic enzyme, application of an ointment of the complex
composition on fissure and entire red border of the lips,
administration of lidocaine blockade with premedication with apo-
diazepam at the dose of 5 mg by sublingual route, using ointment
"Lorinden C", application of He-Ne laser treatment on damaged lip
sites, administration of anti-histaminic prepns., antiallergic
diet and correction of psycho-emotional state. Treatment is
carried out on the background of every day application of oral
gels for lips protection and polyvitamins intake. Homeopathic
ointment "Traumel" is prescribed for children instead of ointment
"Lorinden C". Method ensures high effectiveness of treatment with
the following absence of the relapses of the disease; neuro-

dystrophic, inflammatory processes around lips and perioral skin are eliminated.

ACCESSION NUMBER: 2004:459069 HCAPLUS Full-text
DOCUMENT NUMBER: 141:65131
TITLE: Method for the treatment of chronic relapsing lip fissures and combinations of chronic relapsing lip fissures with exfoliative or atopic chelitis
INVENTOR(S): Brusenina, N. D.; Rybalkina, E. A.
PATENT ASSIGNEE(S): Moskovskii Gosudarstvennyi Mediko-Stomatologicheskii Universitet, Russia
SOURCE: Russ., No pp. given
CODEN: RUXXE7
DOCUMENT TYPE: Patent
LANGUAGE: Russian
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
RU 2227017	C2	20040420	RU 2002-134786	20021224 <--

PRIORITY APPLN. INFO.: RU 2002-134786 20021224 <--
IC ICM A61K009-06
ICS A61N005-06; A61P001-04
CC 1-12 (Pharmacology)
Section cross-reference(s): 2, 7, 8, 18, 63
ST lidocaine proteolytic enzyme sublingual apodiazepam Lorinden C lip fissure; antidepressant antihistaminic antiallergic diet homeopathic ointment Traumel laser
IT Drug delivery systems
(homeopathic, Traumel ointment; method for treatment of chronic relapsing lip fissures and combinations of chronic relapsing lip fissures with exfoliative or atopic chelitis)
IT 137-58-6, Lidocaine 439-14-5, Apo-diazepam 9001-92-7, Proteolytic enzyme
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method for treatment of chronic relapsing lip fissures and combinations of chronic relapsing lip fissures with exfoliative or atopic chelitis)

L11 ANSWER 2 OF 12 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Method for rehabilitation of children with autoimmune thyroiditis and diffuse nontoxic goiter
AB Method is disclosed for rehabilitation of children with autoimmune thyroiditis and diffuse nontoxic goiter. Method involves administration of Thyrospon, medical training exercises, massage and radon baths. General purpose artificial radon baths of 0.75 kBq concentration are administered to children suffering from

autoimmune thyroiditis. General purpose artificial iodine-and-bromide baths with 10 mg/l iodine concentration and 25 mg/l bromine concentration are administered to children suffering from diffuse non-toxic goiter every other day in alternating with collar zone manual massage. Method ensures prolonged remission period.

ACCESSION NUMBER: 2004:240198 HCAPLUS Full-text
DOCUMENT NUMBER: 140:368729
TITLE: Method for rehabilitation of children with autoimmune thyroiditis and diffuse nontoxic goiter
INVENTOR(S): Stepanenko, N. P.; Levitskii, E. F.; Kondrat'eva, E. I.; Shakhova, S. S.
PATENT ASSIGNEE(S): Russia
SOURCE: Russ., No pp. given
CODEN: RUXXE7
DOCUMENT TYPE: Patent
LANGUAGE: Russian
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
RU 2223739	C1	20040220	RU 2002-129512	20021104 <--

PRIORITY APPLN. INFO.: RU 2002-129512 20021104 <--
IC ICM A61H033-00
ICS A61H033-02; A61K035-00
CC 1-12 (Pharmacology)
Section cross-reference(s): 2, 15, 63
IT Drug delivery systems
(homeopathic; method for rehabilitation of children with autoimmune thyroiditis and diffuse nontoxic goiter)
IT 50-23-7, Cortisol 51-48-9, T4, biological studies 6893-02-3, T3 9002-71-5, TSH
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(method for rehabilitation of children with autoimmune thyroiditis and diffuse nontoxic goiter)

L11 ANSWER 3 OF 12 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Drug for treatment of narcotic dependence
AB A preparation to treat narcotic dependence is represented as potentiated forms of antibodies to morphine or morphine hydrochloride, obtained due to subsequent multiple dilution and external impact, predominantly, containing the mixture of homeopathic dilns. A30 and/or A200. Preparation could be used for treatment and secondary prophylaxis of narcotic dependence, mainly, an opium abstinential syndrome and, also, to decrease patient's inclination to narcotic prepns. of different groups, treat psychosomatic disorders as a result of intake of different narcotic prepns., treat abstinential syndrome and affect altered tolerance due to regular intake of narcotic prepns. EFFECT: higher efficiency. 5 cl, 6 ex.

ACCESSION NUMBER: 2002:786991 HCAPLUS Full-text
DOCUMENT NUMBER: 138:61304
TITLE: Drug for treatment of narcotic dependence
INVENTOR(S): Epshtein, O. I.; Kolyadko, T. M.; Shtark, M. B.
PATENT ASSIGNEE(S): Russia
SOURCE: Russ., No pp. given
CODEN: RUXXE7
DOCUMENT TYPE: Patent
LANGUAGE: Russian
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
RU 2182492	C1	20020520	RU 2000-130976	20001214 <--

PRIORITY APPLN. INFO.: RU 2000-130976 20001214 <--
IC ICM A61K039-00
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 4
ST narcotic dependence homeopathic treatment
IT Drug dependence
Human
(homeopathic drug for treatment of narcotic dependence)
IT Drug delivery systems
(homeopathic; homeopathic drug for treatment of narcotic dependence)
IT Antibodies and Immunoglobulins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(to morphine; homeopathic drug for treatment of narcotic dependence)
IT 52-26-6, Morphine hydrochloride 57-27-2, Morphine, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antibodies to; homeopathic drug for treatment of narcotic dependence)

L11 ANSWER 4 OF 12 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Absorbable solid compositions for topical treatment of oral mucosal
disorders
AB A solid, self-bioadhesive composition is provided for topical application that adheres to the oral mucosal tissue comprising a therapeutically effective amount of at least one herbal or homeopathic active agent and a pharmaceutically acceptable solid bioadhesive carrier in an amount of about 40-99% based on the weight of the whole composition A herbal agent is selected from bioactive herb exts., tinctures and essential oils. The composition further comprises a non-herbal active agent, e.g., analgesics, anti-inflammatory agents, antihistaminics, antiallergics, antimicrobial drugs, vitamins, enzymes, etc. For example, tablets were prepared by compression molding of herbal and non-herbal actives in powder form and mixts. of Carbopol 934 and HPMC. The formulation contained a herbal powder (an equal

ratio of Echinacea, Calendula and golden seal exts.) 10 mg, vancomycin 1 mg, Carbopol 934 50 mg, and mint extract 5 mg. The cap coating was composed of a mixture of 5 mg of Mg-stearate and 5 mg Carbopol/HPMC (2:1 by weight). The preparation was used by patients exhibiting herpetic stomatitis lesions, aphthous ulcers, mucosal inflammation, toothache, RAS, and lesions on the lips, tang, and gingiva.

ACCESSION NUMBER: 2002:671827 HCAPLUS Full-text
DOCUMENT NUMBER: 137:206549
TITLE: Absorbable solid compositions for topical treatment of oral mucosal disorders
INVENTOR(S): Domb, Avraham J.; Wolnerman, Joseph Simcha
PATENT ASSIGNEE(S): Efrat Biopolymers Ltd., Israel
SOURCE: Eur. Pat. Appl., 25 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1236466	A1	20020904	EP 2002-251320	20020226 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
PRIORITY APPLN. INFO.: US 2001-271735P P 20010228 <--
IC ICM A61K009-00
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1
ST essential oil herbal ext tincture homeopathic prepn topical; oral mucosa bioadhesive solid essential oil herb homeopathic prepn
IT Drug delivery systems
(homeopathic; absorbable solid compns. for topical treatment of oral mucosal disorders)
IT 50-02-2, Dexamethasone 50-23-7, Hydrocortisone 50-36-2, Cocaine 55-56-1, Chlorhexidine 59-46-1, Procaine 60-54-8, Tetracycline 68-35-9, Sulfadiazine 73-40-5, Guanine 75-47-8, Iodoform 76-22-2, Camphor 76-57-3, Codeine 79-10-7D, Acrylic acid, esters, polymers 79-41-4D, Methacrylic acid, esters, polymers 85-79-0, Dibucaine 94-09-7, Benzocaine 94-24-6, Tetracaine 96-88-8, Mepivacaine 99-96-7D, p-Hydroxybenzoic acid, esters 108-95-2, Phenol, biological studies 124-94-7, Triamcinolone 133-16-4, Chloroprocaine 137-58-6, Lidocaine 138-86-3, Limonene 288-88-0, 1H-1,2,4-Triazole 586-60-7, Dyclonine 721-50-6, Prilocaine 738-70-5, Trimethoprim 1318-27-0, Carnallite 1397-89-3, Amphotericin B 1400-61-9,

Nystatin
3380-34-5, Triclosan 6277-14-1, Acetoxolone 6809-52-5, Teprenone
7447-40-7, Potassium chloride, biological studies 7631-86-9, Silica,
biological studies 7647-14-5, Sodium chloride, biological studies
7681-49-4, Sodium fluoride, biological studies 7789-48-2, Magnesium
bromide 9000-30-0, Guar-gum 9000-69-5, Pectin 9002-89-5, Poly(vinyl
alcohol) 9003-01-4, Poly(acrylic acid) 9004-32-4, Carboxymethyl
cellulose sodium 9004-34-6D, Cellulose, derivs. 9004-54-0, Dextran,
biological studies 9004-61-9, Hyaluronic acid 9004-62-0, Hydroxyethyl
cellulose 9004-64-2, Hydroxypropyl cellulose 9004-65-3, Hydroxypropyl
methyl cellulose 9005-25-8D, Starch, derivs. 9007-16-3, Carbopol 934
9025-70-1, Dextranase 9036-66-2, Arabinogalactan 9057-02-7, Pullulan
13463-67-7, Titanium dioxide, biological studies 14807-96-6, Talc,
biological studies 15687-27-1, Ibuprofen 22916-47-8, Miconazole
25322-68-3, Polyethylene oxide 25655-41-8, Povidone-iodine 27254-80-4,
Acridinamine 36637-18-0, Etidocaine 38396-39-3, Bupivacaine
54182-58-0, Sucralfate 59277-89-3, Acyclovir 73590-58-6, Omeprazole
76050-42-5, Carbopol 940 82419-36-1, Ofloxacin 84625-61-6, Itraconazole
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(absorbable solid compns. for topical treatment of oral mucosal disorders)
OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(2 CITINGS)
REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 5 OF 12 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Curative method for pathologic syndromes and homeopathic medicinal preparations
AB The inventive curative method for a pathol. syndrome consists in inserting into an organism activated forms of minute antibody doses which are produced by means of a repeated successive dilution and an external action carried out on an antigen, e.g. a substance or medicinal preparation influencing a mechanism forming said pathol. syndrome. The inventive medicinal preparation for curing the pathol. syndrome comprises an activated form of minute doses of monoclonal, polyclonal or natural antibodies. Said antibodies are produced by means of a repeated successive dilution

and an external action, preferably using homeopathic technol., which is carried out on an antigen, e.g. a substance or medicinal preparation directly promoting the formation of the pathol. syndrome or participating in regulating mechanisms for the formation thereof. Activated forms of minute doses of antibodies to the antigens of an exogenic and endogenic nature, autoantigens and fetal antigens, are used. Anti-idiotypic antibodies are also used.

ACCESSION NUMBER: 2001:935434 HCAPLUS Full-text
DOCUMENT NUMBER: 136:58848
TITLE: Curative method for pathologic syndromes and homeopathic medicinal preparations
INVENTOR(S): Epshtein, Oleg Iliich; Kolyadko, Tamara Mikhailovna; Shtark, Mark Borisovich
PATENT ASSIGNEE(S): Russia
SOURCE: PCT Int. Appl., 100 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Russian
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001097842	A1	20011227	WO 2001-RU239	20010619 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
RU 2181297	C2	20020420	RU 2000-115594	20000620 <--
CA 2413358	A1	20011227	CA 2001-2413358	20010619 <--
AU 2001069646	A	20020102	AU 2001-69646	20010619 <--
EP 1295606	A1	20030326	EP 2001-948169	20010619 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 20030099636	A1	20030529	US 2002-311666	20021217 <--
US 20070224187	A1	20070927	US 2007-656226	20070122 <--

US 20080019982 A1 20080124 US 2007-656322
20070122 <--
US 20080025985 A1 20080131 US 2007-656225
20070122 <--
US 20080050392 A1 20080228 US 2007-656217
20070122 <--
US 20080050360 A1 20080228 US 2007-656218
20070122 <--
US 20080131440 A1 20080605 US 2007-656216
20070122 <--
PRIORITY APPLN. INFO.: RU 2000-115594 A
20000620 <--
WO 2001-RU239 W
20010619 <--
US 2002-311666 A3
20021217 <--
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
IC ICM A61K039-395
ICS A61P037-00
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 15
ST antibody homeopathic formulation
IT Blood-group substances
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Rh, antibodies to; curative method for pathol. syndromes and homeopathic medicinal prepns.)
IT Cannabinoids
Interferons
Prostaglandins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antibodies to; curative method for pathol. syndromes and homeopathic medicinal prepns.)
IT Antibodies and Immunoglobulins
Antigens
Haptens
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process);
USES (Uses)
(curative method for pathol. syndromes and homeopathic medicinal prepns.)
IT Drug delivery systems
(homeopathic; curative method for pathol. syndromes and homeopathic medicinal prepns.)
IT Antibodies and Immunoglobulins
RL: PEP (Physical, engineering or chemical process); PYP (Physical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process);
USES (Uses)
(monoclonal; curative method for pathol. syndromes and homeopathic medicinal prepns.)
IT 50-02-2 50-06-6, Phenobarbital, biological studies 50-23-7, Hydrocortisone 50-28-2, Estradiol, biological studies 50-35-1, Thalidomide 50-37-3, Lsd 50-48-6, Amitriptyline 50-49-7, Imipramine
50-55-5, Reserpine 50-67-9, Serotonin, biological studies 50-78-2,

Aspirin 51-41-2, Noradrenalin 51-45-6, Histamine, biological studies
51-55-8, Atropine, biological studies 51-60-5, Proserine 51-61-6,
Dopamine, biological studies 51-84-3, Acetylcholine, biological studies
52-53-9, Verapamil 52-86-8, Haloperidol 53-86-1, Indomethacin
54-11-5, Nicotine 54-31-9, Furosemide 54-85-3, Isoniazid 55-63-0,
Nitroglycerin 56-40-6, Glycine, biological studies 56-84-8, Aspartic
acid, biological studies 56-86-0, Glutamic acid, biological studies
57-27-2, Morphine, biological studies 57-41-0, Phenytoin
57-47-6, Physostigmine 57-66-9, Probenecid 57-92-1, Streptomycin,
biological studies 58-08-2, Caffeine, biological studies 58-22-0,
Testosterone 58-55-9, Theophylline, biological studies 58-82-2,
Bradykinin 58-93-5, Hypothiazide 59-05-2, Methotrexate 59-26-7,
Cordiamine 59-43-8, Thiamin, biological studies 59-66-5, Acetazolamide
59-67-6, Nicotinic acid, biological studies 59-92-7, Levo-dopa,
biological studies 60-99-1, Tisercin 64-39-1, Promedol 71-63-6,
Digitoxin 71-73-8, Thiopental sodium 76-57-3, Codeine 77-10-1,
Phencyclidine 86-54-4, Apressin 87-33-2, Nitrosorbide 92-84-2,
Phenothiazine 97-77-8, Disulfiram 103-90-2, Paracetamol 137-58-6,
Lidocaine 146-22-5, Nitrazepam 298-46-4, Tegretol 299-42-3,
Ephedrine 318-98-9, Anapriline 364-62-5, Metoclopramide 437-38-7,
Fentanil 439-14-5, Diazepam 443-48-1, Metronidazole
465-65-6, Naloxone 511-12-6, Dihydroergotamine 586-06-1, Orciprenaline
621-72-7, Dibazol 835-31-4, Naphthizine 982-43-4, Libexin 985-12-6,
No-spa 1069-66-5, Depakin 1078-21-3, Phenibut 1134-47-0, Baclofen
1406-16-2, Vitamin d 1406-18-4, Vitamin e 1490-04-6, Menthol
1972-08-3, Tetrahydrocannabinol 2898-12-6, Mezapam 3644-61-9, Midocalm
3737-09-5, Ritmilen 3930-20-9, Sotalol 4205-91-8, Clofelin
5786-21-0, Azaleptine 6740-88-1, Ketamine 6893-02-3, Triiodothyronine
7085-55-4, Troxerutin 7491-74-9, Nootropil 9002-72-6, Somatotropin
9004-10-8, Insulin, biological studies 9005-49-6, Heparin, biological
studies 9007-12-9, Calcitonin 9007-92-5, Glucagon, biological studies
9015-82-1, Angiotensin-converting enzyme 9015-94-5, Renin, biological

studies 9025-82-5, Phosphodiesterase 9035-34-1, Cytochrome a
10540-29-1, Tamoxifen 11103-57-4, Vitamin A 11128-99-7,
Angiotensin ii
12656-61-0, Cerebrolysin 13292-46-1, Rifampicin 13311-84-7,
Flutamide
13392-18-2, Fenoterol 14286-84-1, Halidor 14402-89-2, Sodium
nitroprusside 14611-51-9, Selegiline 14769-73-4, Levamisol
14838-15-4, Norephedrine 14976-57-9, Tavegil 15307-86-5,
Diclofenac
15663-27-1, Cisplatin 15687-27-1, Ibuprofen 15876-67-2,
Ubretid
16110-51-3, Cromolyn 16773-42-5, Ornidazole 17479-19-5,
Dihydroergocristine 18559-94-9, Salbutamol 19216-56-9,
Prazosin
19774-82-4, Cordarone 20830-75-5, Digoxin 22254-24-6, Atrovent
23214-92-8, Doxorubicin 23288-49-5, Probucol 23476-83-7,
Prospidine
25614-03-3, Bromocryptine 25717-80-0, Molsidomine 27236-88-0,
Sodium
hydroxybutyrate 28797-61-7, Pirenzepine 29122-68-7, Atenolol
31637-97-5, Etofibrate 34262-84-5 34580-13-7, Ketotifen
34580-14-8,
Zaditen 36282-47-0, Tramal 36894-69-6 39391-18-9,
Cyclooxygenase
42399-41-7, Diltiazem 42408-82-2, Butorphanol 51753-57-2,
Phenazepam 54063-53-5, Propafenone 54739-18-3, Fluvoxamine
54910-89-3, Fluoxetine 55142-85-3, Ticlopidine 57808-66-9,
Motilium
59122-46-2, Misoprostol 59467-70-8, Midazolam 62571-86-2,
Captopril
62683-29-8, Colony stimulating factor 66357-35-5, Ranitidine
66829-00-3, Aminalone 71320-77-9, Moclobemide 72841-18-0,
Cytochrome
a3 73590-58-6, Omeprazole 75438-57-2, Moxonidine 75847-73-3,
Enalapril 76824-35-6, Famotidine 79617-96-2, Sertraline
79794-75-5,
Loratadine 80214-83-1, Rulid 81093-37-0, Pravastatin 82626-
48-0,
Zolpidem 84057-84-1, Lamotrigin 85721-33-1, Ciprofloxacin
88040-23-7, Tsefepim 96829-58-2, Orlistat 103628-46-2,
Sumatriptan
106266-06-2, Risperidone 106463-17-6, Omnic 110942-02-4,
Aldesleukin
111470-99-6, Norvasc 121181-53-1, Filgrastim 124750-99-8,
Cozaar
142805-56-9, Topoisomerase ii 214692-62-3, Omez 383123-63-5,
Detralex
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antibodies to; curative method for pathol. syndromes and
homeopathic medicinal prepns.)
OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE
THIS RECORD
(6 CITINGS)
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE
FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE
RE FORMAT

L11 ANSWER 6 OF 12 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Analgesic, antipyretic, anti-inflammatory, flu-preventing medicine
AB An analgesic, antipyretic, anti-inflammatory, anti-influenzal preparation is disclosed which comprises (parts by weight) aspirin 10-500, paracetamol or ascorbic acid 10-500, caffeine 1-50, diazepam 1-50 or amitryptiline 1-20 or thioridazine 1-20, or hydroxizine 1-20 or promethazine 1-30, or a mixture of 1-50 parts phenylpropanolamine and 1-50 parts chlorpheniramine or a mixture of 10-5000 parts propyphenazone and 1-50 parts codeine and a mixture of 1-50 parts homeopathic prepns. of Aconitum, Gelsemium, Eupatorium, Echinacea, Bryonia, or a mixture of 0.01-10 parts homeopathic prepns. of white arsenic, Hydrastis, Phytolacca, Medorrhinum, Mezereum, iron phosphate, Influenzium, phosphorus triiodate, Sambucus, and pharmaceutically acceptable excipients. The preparation may be formed into tablets or capsules.
ACCESSION NUMBER: 2001:189220 HCAPLUS Full-text
DOCUMENT NUMBER: 134:212698
TITLE: Analgesic, antipyretic, anti-inflammatory, flu-preventing medicine
INVENTOR(S): Dobrescu, Dumitru
PATENT ASSIGNEE(S): Rom.
SOURCE: Rom., 3 pp.
CODEN: RUXXA3
DOCUMENT TYPE: Patent
LANGUAGE: Romanian
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
RO 113712	B3	19981030	RO 1996-353	19960222 <--

PRIORITY APPLN. INFO.: RO 1996-353 19960222 <--
IC ICM A61K009-28
CC 63-6 (Pharmaceuticals)
IT Drug delivery systems
(homeopathic; analgesic, antipyretic, anti-inflammatory, flu-preventing formulation)
IT 50-48-6 50-52-2, Thioridazine 50-78-2, Aspirin 50-81-7, Ascorbic
acid, biological studies 58-08-2, Caffeine, biological studies 60-87-7, Promethazine 68-88-2, Hydroxizine 76-57-3, Codeine 103-90-2, Paracetamol 113-92-8, Chlorpheniramine 439-14-5, Diazepam 479-92-5, Propyphenazone 14838-15-4, Phenylpropanolamine
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(analgesic, antipyretic, anti-inflammatory, flu-preventing formulation)
OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L11 ANSWER 7 OF 12 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Mechanisms of behavioral effects of potentiated morphine forms
AB Effects of morphine and its potentiated (homeopathic) form on rat behavior in an elevated plus-maze were studied. Combined application of potentiated and non-potentiated morphine enhanced the anxiolytic and sedative effects. Patch-clamp expts. on isolated Helix pomatia giant neurons revealed a blocking effect of potentiated morphine on μ-receptors.
ACCESSION NUMBER: 2000:510920 HCAPLUS Full-text
DOCUMENT NUMBER: 133:329389
TITLE: Mechanisms of behavioral effects of potentiated morphine forms
AUTHOR(S): Epshtein, O. I.; Zapara, T. A.; Pavlov, I. F.; Simonova, O. G.
CORPORATE SOURCE: Materia Medica Research-and-Production Company, Moscow, Russia
SOURCE: Bulletin of Experimental Biology and Medicine (Translation of Byulleten Eksperimental'noi Biologii i Meditsiny) (2000), Volume Date 1999, 128(12), 1196-1198
CODEN: BEXBAN; ISSN: 0007-4888
PUBLISHER: Consultants Bureau
DOCUMENT TYPE: Journal
LANGUAGE: English
CC 1-11 (Pharmacology)
IT 57-27-2D, Morphine, potentiated
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(behavioral effects of potentiated morphine forms)
REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 8 OF 12 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Method for the treatment of drug addiction and homeopathic remedy
AB A method of therapy for drug addiction is claimed. Potentiated morphine, prepared by repeated and successive dilution and agitation of morphine solution or a mixture of opium alkaloids containing 50-95 weight% morphine, morphine hydrochloride, and apomorphine or other morphine derivs. are used practically as homeopathic prepns. The combined administration of potentiated morphine and an addnl. potentiated homeopathic remedy, derived from the original habitual narcotic substance for which a patient has a pathol. craving, is suggested for periods of critical intoxication and abstinence.
ACCESSION NUMBER: 1998:572337 HCAPLUS Full-text
DOCUMENT NUMBER: 129:170539
ORIGINAL REFERENCE NO.: 129:34512h,34513a
TITLE: Method for the treatment of drug addiction and

homeopathic remedy
INVENTOR(S): Epshtein, Oleg Iliich
PATENT ASSIGNEE(S): Russia
SOURCE: PCT Int. Appl., 13 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Russian
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9835680	A1	19980820	WO 1998-RU23	19980209 <--
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
RU 2104006	C1	19980210	RU 1997-101895	19970214 <--
AU 9861264	A	19980908	AU 1998-61264	19980209 <--
PRIORITY APPLN. INFO.:			RU 1997-101895	A 19970214 <--
			WO 1998-RU23	W 19980209 <--

IC ICM A61K314-85
CC 1-11 (Pharmacology)
Section cross-reference(s): 4, 63
ST therapy drug addiction homeopathic opium alkaloid
IT Drug delivery systems
(homeopathic; method for treatment of drug addiction by homeopathic prepns. of opium alkaloids)
IT Alcoholism
Drug dependence
Drug withdrawal
(method for treatment of drug addiction by homeopathic prepns. of opium alkaloids)
IT Opioids
RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(method for treatment of drug addiction by homeopathic prepns. of opium alkaloids)
IT 50-36-2, Cocaine 50-37-3, LSD 52-26-6, Morphine hydrochloride 57-27-2, Morphine, biological studies 58-00-4, Apomorphine 64-17-5, Ethanol, biological studies
RL: ADV (Adverse effect, including toxicity); THU (Therapeutic

use); BIOL
(Biological study); USES (Uses)
(method for treatment of drug addiction by homeopathic preps. of opium alkaloids)
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 9 OF 12 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Opium alkaloid pharmaceuticals for inhibition of psychophysiological
homeostasis
AB Title only translated.
ACCESSION NUMBER: 1998:301140 HCAPLUS Full-text
DOCUMENT NUMBER: 128:286392
ORIGINAL REFERENCE NO.: 128:56605a,56608a
TITLE: Opium alkaloid pharmaceuticals for inhibition of
psychophysiological homeostasis
INVENTOR(S): Vorobeva, Tamara Mikhajlovna; Epshtejn, Oleg I.;
Ilchikov, Mikhail Z.
PATENT ASSIGNEE(S): Vorobeva, Tamara Mikhajlovna, Ukraine; Epshtejn, Oleg
Ilich; Ilchikov, Mikhail Zakharovich
SOURCE: Russ. From: Izobreteniya 1997, (33), 273.
CODEN: RUXXE7
DOCUMENT TYPE: Patent
LANGUAGE: Russian
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
RU 2097035	C1	19971127	RU 1996-123693	19961220 <--

PRIORITY APPLN. INFO.: RU 1996-123693 19961220 <--
IC ICM A61K031-485
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1
IT Drug delivery systems
(homeopathic; opium alkaloid pharmaceuticals for inhibition of psychophysiol. homeostasis)
IT 52-26-6, Morphine hydrochloride 57-27-2, Morphine, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
(Uses)
(opium alkaloid pharmaceuticals for inhibition of psychophysiol.
homeostasis)

L11 ANSWER 10 OF 12 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Agent for acting upon the organism
AB The present invention relates to an agent for acting upon the organism and to biol. active substances. This invention more precisely relates to a potential preparation which is obtained by repeatedly cultivating and shaking a specific starting product having toxic properties and being poisonous to the organism (narcotics, alc., nicotine, industrial poisons, military poisonous substances). In order to cure alcoholism, this method uses ethanol as a starting substance during the potentialization, while it uses an opium alkaloid, morphine or morphine hydrochloride for curing drug problems. The potential agent of the present invention may be used in any medical homeopathic form and preferably together with the starting product.

ACCESSION NUMBER: 1998:219690 HCAPLUS Full-text
DOCUMENT NUMBER: 128:279704
ORIGINAL REFERENCE NO.: 128:55292h,55293a
TITLE: Agent for acting upon the organism
INVENTOR(S): Epshtein, Oleg Iliich
PATENT ASSIGNEE(S): Epshtein, Oleg Iliich, Russia
SOURCE: PCT Int. Appl., 10 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Russian
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9814162	A1	19980409	WO 1997-RU305	19970929 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
RU 2132181	C1	19990627	RU 1996-118931	19960930 <--
AU 9747293	A	19980424	AU 1997-47293	19970929 <--
PRIORITY APPLN. INFO.:			RU 1996-118931	A 19960930 <--
			WO 1997-RU305	W 19970929 <--

IC ICM A61J003-00
ICS A61K031-045; A61K031-485; A61K035-78
CC 4-7 (Toxicology)
Section cross-reference(s): 1

IT 52-26-6, Morphine hydrochloride 57-27-2, Morphine, biological studies 64-17-5, Ethanol, biological studies
RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(chemical and drug toxicity and the potential treatment)
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 11 OF 12 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Characterization of homeopathic drugs
AB cf. C. A. 22, 4718. Detailed procedures are indicated for the evaluation of apomorphine-HCl, morphine-HCl, codeine phosphate, HgCl2, Hg(OCN)2, Hg2Cl2 and HgI2 in their several potencies.
ACCESSION NUMBER: 1929:21338 HCAPLUS Full-text
DOCUMENT NUMBER: 23:21338
ORIGINAL REFERENCE NO.: 23:2532a-b
TITLE: Characterization of homeopathic drugs
AUTHOR(S): Neugebauer, H.
SOURCE: Apoth. Ztg. (1929), 44, 381-4
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
CC 17 (Pharmaceutical Chemistry)
IT 52-28-8, Codeine, phosphate 57-27-2, Morphine 314-19-2, Apomorphine, -hydrochloride 51312-24-4, Mercury chloride
(assay of)

L11 ANSWER 12 OF 12 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Effect of homeopathic remedies upon intestinal movement and the action of veratrum viride upon muscular tissue
AB Segments of the small intestine of a freshly killed rabbit were immersed in oxygenated Ringer-Lagendorf solution at 38°, and were treated with the drug. A 1% solution of K2SO4.Al2(SO4)3 produced an immediate cessation of intestinal activity, and a slight shortening of the intestinal segment. Tincture of tabacum, from which the alc. had been removed by gentle heating on the water bath, caused an immediate contraction of the intestinal segment, corresponding to vigorous peristaltic activity; "usually there would be one such increased movement recorded and the segment consumed from 3 to 5 times the time in making it that it did in performing a normal peristaltic wave." When 0.5 grain of morphine sulfate was dissolved in 265 cc. of the Ringer solution, the amplitude of the peristaltic activity was immediately reduced to approx. half normal, while the rate movement of the intestine was not appreciably affected. Tincture of Veratrum viride was modified by removal of its alc., using a gentle heat. "A ligature was laid around 1 thigh of a frog to cut off the circulation, and 1 cc. of the modified tincture injected into the dorsal lymph sac. After waiting 20 min. for absorption, tracings were made of the normal gastrocnemius muscle (which was removed and placed in a moist chamber apparatus), as influenced by elec. stimulation. While the normal muscle was being tested, the drugged muscle had its circulation cut off for 20 min. so as to have both muscles in the same state of asphyxiation. Tracings were made from the drugged gastrocnemius in the same manner as in the case of the

normal muscle. A comparison of the 2 tracings showed that the muscle which had been acted upon by the veratrum comtracted more vigorously, i. e., to smaller size thus the normal muscle and that there is a marked tendency for the drugged muscle to relax very slowly. Also the muscle contracts again before it is completely relaxed." This drug has a similar action on warm-blooded animals, and probably on man.

ACCESSION NUMBER: 1918:11748 HCAPLUS Full-text
DOCUMENT NUMBER: 12:11748
ORIGINAL REFERENCE NO.: 12:2018f-i,2019a
TITLE: Effect of homeopathic remedies upon intestinal movement and the action of veratrum viride upon muscular tissue
AUTHOR(S): Hinsdale, Albert E.
CORPORATE SOURCE: Ohio State Univ.
SOURCE: Journal of the American Institute of Homeopathy (1918), 10, 1243-6
CODEN: JAIHAQ; ISSN: 0002-8967
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
CC 11H (Biological Chemistry: Pharmacology)
IT Intestines
(homeopathic remedies and)
IT 57-27-2, Morphine 10043-67-1, Aluminum potassium sulfate
(effect on intestinal movement)

L12 3 S L10 NOT L11
L13 2 S L12 NOT L1

L13 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Potentiated cyclophosphane: Experimental study of the effect on tumor development and efficiency of cytostatic therapy
AB Expts. on animals with transplanted tumors (Lewis lung carcinoma and carcinosarcoma Walker-256) showed that combination treatment with cyclophosphane and its homeopathically potentiated forms increases antiblastic activity of the preparation

ACCESSION NUMBER: 2003:542972 HCAPLUS Full-text
DOCUMENT NUMBER: 141:64483
TITLE: Potentiated cyclophosphane: Experimental study of the effect on tumor development and efficiency of cytostatic therapy
AUTHOR(S): Amosova, E. N.; Zueva, E. P.; Razina, T. G.; Krylova, S. G.; Shilova, N. V.; Epstein, O. I.
CORPORATE SOURCE: Tomsk Research Center, Institute of Pharmacology, Siberian Division of the Russian Academy of Medical

Sciences, Tomsk, Russia
SOURCE: Bulletin of Experimental Biology and Medicine (Translation of Byulleten Eksperimental'noi Biologii i Meditsiny) (2003), 135-136(Suppl. 1), 107-110
CODEN: BEXBAN; ISSN: 0007-4888
PUBLISHER: Kluwer Academic/Consultants Bureau
DOCUMENT TYPE: Journal
LANGUAGE: English
CC 1-6 (Pharmacology)
ST cyclophosphane potentiated homeopathic bipathic antitumor cytostatic lunch carcinoma
IT 50-18-0, Cyclophosphane
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(effect of potentiated cyclophosphane on tumor development and efficiency of cytostatic therapy)
REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Effect of Potentiated Antibodies to Cyclophosphamide on the Development of Tumors and Effectiveness of Cytostatic Therapy under Experimental Conditions
AB Antibodies to cyclophosphamide obtained by homeopathic potentiation and administered in ultralow doses exhibit no antiblastic activity and did not modulate the effectiveness of cyclophosphamide during antitumor therapy of animals with transplanted tumors (Lewis lung carcinoma and Ehrlich adenocarcinoma).
ACCESSION NUMBER: 2003:542932 HCAPLUS Full-text
DOCUMENT NUMBER: 140:302022
TITLE: Effect of Potentiated Antibodies to Cyclophosphamide on the Development of Tumors and Effectiveness of Cytostatic Therapy under Experimental Conditions
AUTHOR(S): Amosova, E. N.; Zueva, E. P.; Razina, T. G.; Krylova, S. G.; Shilova, N. V.; Epstein, O. I.
CORPORATE SOURCE: Tomsk Research Center, Institute of Pharmacology, Siberian Division of the Russian Academy of Medical Sciences, Moscow, Russia
SOURCE: Bulletin of Experimental Biology and Medicine (Translation of Byulleten Eksperimental'noi Biologii i Meditsiny) (2003), 135-136(Suppl. 1), 54-56
CODEN: BEXBAN; ISSN: 0007-4888
PUBLISHER: Kluwer Academic/Consultants Bureau
DOCUMENT TYPE: Journal

LANGUAGE: English
CC 15-3 (Immunochemistry)
Section cross-reference(s): 1
IT 50-18-0, Cyclophosphamide
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(effect of potentiated antibodies to cyclophosphamide on the development of tumors and effectiveness of cytostatic therapy under
exptl. conditions)
REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT